TScan Therapeutics (NASDAQ:TCRX) Price Target Lowered to $15.00 at HC Wainwright

TScan Therapeutics (NASDAQ:TCRX – Get Rating) had its price target decreased by HC Wainwright from $21.00 to $15.00 in a report released on Tuesday, The Fly reports.

Separately, Zacks Investment Research downgraded TScan Therapeutics from a buy rating to a hold rating in a research report on Tuesday, March 15th. One analyst has rated the stock with a hold rating and five have given a buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of Buy and a consensus price target of $16.35.

Shares of TCRX opened at $2.49 on Tuesday. TScan Therapeutics has a 1 year low of $1.60 and a 1 year high of $14.71. The business has a 50-day moving average of $2.75 and a 200-day moving average of $4.82.

In other TScan Therapeutics news, CFO Brian M. Silver bought 15,000 shares of the stock in a transaction on Thursday, March 24th. The stock was acquired at an average cost of $3.40 per share, for a total transaction of $51,000.00. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.

A number of hedge funds have recently modified their holdings of the business. BlackRock Inc. increased its holdings in TScan Therapeutics by 1.4% in the first quarter. BlackRock Inc. now owns 1,519,188 shares of the company’s stock worth $4,254,000 after purchasing an additional 20,650 shares in the last quarter. RA Capital Management L.P. acquired a new stake in TScan Therapeutics in the third quarter valued at approximately $10,469,000. Deer Management Co. LLC acquired a new stake in TScan Therapeutics in the fourth quarter valued at approximately $5,605,000. DC Funds LP acquired a new stake in TScan Therapeutics in the third quarter valued at approximately $5,254,000. Finally, Adage Capital Partners GP L.L.C. grew its stake in TScan Therapeutics by 10.8% in the fourth quarter. Adage Capital Partners GP L.L.C. now owns 550,000 shares of the company’s stock valued at $2,475,000 after acquiring an additional 53,417 shares during the period. Institutional investors and hedge funds own 36.97% of the company’s stock.

TScan Therapeutics Company Profile (Get Rating)

TScan Therapeutics, Inc, a preclinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell therapies for the treatment of patients with cancer. It is developing TSC-100 and TSC-101 for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation; and TSC-200, TSC-201, TSC-202, TSC-203, and TSC-204 for the treatment of solid tumors.

Featured Articles